טוען...
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
With the FDA approval of larotrectinib, NTRK fusion assessment has recently become a standard part of management for patients with locally advanced or metastatic cancers. Unlike somatic mutation assessment, the detection of NTRK fusions is not straightforward, and various assays exist at the DNA, RN...
שמור ב:
| הוצא לאור ב: | Mod Pathol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7437403/ https://ncbi.nlm.nih.gov/pubmed/31375766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41379-019-0324-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|